# Obsidian Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/obsidian-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.obsidiantx.com
- Total disclosed funding: $308M
- Latest round: Series C (Apr 3, 2024)
- Investors on record: 27

## About

Based in Massachusetts, US, and founded in 2015, Obsidian Therapeutics, Inc. is a biotechnology company dedicated to the development of next-generation cell and gene therapies for the treatment of cancer. The company was co-founded by Michael Gilman, Steve Shamah, and Tariq Kassum and is backed by investors including GV and The Column Group Crossover Fund, which led a USD 115 million Series B funding round in September 2021. In April 2024, Obsidian Therapeutics, Inc. raised USD 160.5 million in a Series C funding led by Wellington Management, with participation from Atlas Venture, Blue Owl Capital, Bristol-Myers Squibb Company, Deep Track Capital, Foresite Capital, Janus Henderson Investors, Logos Capital, Novo Holdings, Paradigm Biocapital Advisors Lp, RA Capital Management, RTW Investments, Surveyor Capital, TCG Crossover Management, Samsara BioCapital, Surveyor Capital, T Rowe Price, and Woodline Partners. The series C funding values Obsidian Therapeutics, Inc. at USD 503.80 million post-money.

Obsidian has developed platform technologies that allow for exquisite control of protein activity in cells, thereby enabling tunable cell and gene therapies. The cytoDRiVE® platform supports drug-responsive domains (DRDs) to control protein function using an FDA-approved small molecule. The company is developing a tumor-infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma.

Obsidian plans to use its proceeds from April 2024 funding to accelerate its transformative cytoTIL15 program, conduct clinical studies to treat patients with solid tumors, further expand it to other solid tumor types, and advance its commercial manufacturing build.

## Funding rounds

- Series C, Apr 3, 2024, $161M — Atlas Venture, T Rowe Price, Novo Holdings, Wellington Management, Bristol-Myers Squibb Company, Foresite Capital, RTW Investments, RA Capital Management, Janus Henderson Investors, Samsara BioCapital, Surveyor Capital, Logos Capital, TCG Crossover Management, Blue Owl, Deep Track Capital, Woodline Partners, Paradigm Biocapital Advisors Lp
- Series B, Sep 9, 2021, $115M — Atlas Venture, Amgen Ventures, Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, RA Capital Management, Vertex Ventures HC, Pivotal Life Sciences, Samsara BioCapital, Surveyor Capital, Soleus Capital, Logos Capital, Cowen Healthcare Investments, TCG Crossover Management, Deep Track Capital
- Series A, Dec 6, 2017, $32M — Atlas Venture, Alexandria Venture Investments, Amgen Ventures, GV, Shanghai ChemPartner Co., Ltd., Takeda Ventures, Vertex Ventures HC

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A, Series B
- GV (https://capitalatlas.ai/funds/gv) — Series A
- Shanghai ChemPartner Co., Ltd. — Series A
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A
- Vertex Ventures HC (https://capitalatlas.ai/funds/vertex-ventures-hc) — Series A, Series B
- Bristol-Myers Squibb Company — Series B, Series C
- Vertex Pharmaceuticals Incorporated — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B, Series C
- Surveyor Capital — Series B, Series C
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B, Series C
- Cowen Healthcare Investments — Series B
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series B, Series C
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B, Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- Novo Holdings — Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series C
- Janus Henderson Investors — Series C
- Blue Owl (https://capitalatlas.ai/funds/blue-owl) — Series C
- Woodline Partners — Series C
- Paradigm Biocapital Advisors Lp — Series C